CHCWM – Cancer & Hematology Centers of West Michigan

CLN-619-001  (Cullinan)

CLN-619-001  (Cullinan)

Description:  A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors

 Mechanism of Action: Monoclonal antibody that specifically binds the NKG2D ligands MICA and MICB and prevents their proteolytic release from the surface of tumor cells, thereby enhancing tumor cell lysis by NKG2D-expressing immune cells.

 Target Patient Population:  All solid tumors.  Monotherapy arms and combination arms administered with Pembrolizumab

Study Design:  Drug is administered IV weekly in a 21 day cycle